Member Info for thetriplestar

If Solvonis proves that their thin film is "bioequivalent" (delivers the drug as well as Spravato), they essentially own a "de-risked" version of a multi-billion dollar drug. Big Pharma often buys these assets early to protect their own franchises or to block competitors from entering. Very exciting times...

Johnson & Johnson's Q4 2025 results showed Spravato (esketamine) revenue surged over 50% year-on-year, with Q4 alone bringing in over $500 million. J&J has publicly stated that Spravato is on a "blockbuster" trajectory, with peak annual sales expected between $1bn and $5bn. Unlike Spravato’s nasal spray (which requires a mandatory 2-hour medical observation), SVN-002 is a sublingual (under the tongue) thin film. If the data shows it can be administered with less intensive supervision, it becomes a "successor technology" that is much easier to scale. So we could be in for a wild ride for sure!

I take those large trades buying SVNS stocks as a great sign.... positioning....before the WuXi data is released...

It's tempting to think the worst when the cameras stop rolling. But look at the March 5th Annual Report again—Nick Tulloch literally said, "We all have considerable cause for optimism as we become a gold producer." He wouldn't put that in a signed, audited legal document if the wash plant was a heap of scrap metal. He is a City veteran; he knows that the "First Gold" RNS is his biggest card, and he’s waiting to play it perfectly.

Https://songwe-helium.com

Just checked Songwe website - no update yet - still not released.

Glad to see a few people are actually checking the tapes. I dropped that “Expert Market” glitch in just to see who was chasing ghost tickers and who was paying attention to the actual company news. Consider it a quick pulse check on the board. And the pulse was instant so well done 😄

Rae le'COCO - you need to read things properly - plenty of info in the public domain to absorb to enhance your understanding of ECR Ops and future potential. Maybe if you did that we wouldn't feel so obliged to help out someone like you who perhaps is lacking a rather basic understanding of what is going on here.

Indeed - ajSimons how long would have it taken you to realise this - any price action there is just Pink Sheet noise perhaps... maybe a screenshot from long lost times when a $1 trade sent that prince flying haha -

The 92% jump is the US ticker "catching up" to the value already proven in London. It shows that the US market is finally pricing in the Qatar Crisis and the 9.2% discovery.

This is the clearest roadmap for Rukwa yet. The EPS is our secret weapon because it allows us to stop being an 'explorer' and start being a producer almost immediately. By skipping the multi-year wait for a massive central plant and going modular with about 5 wells, we can generate early cash flow while gathering the data that Tier-1 partners need to see.

Combined with the 9.2% concentration and the revenue already ramping up from the US (Galactica), this phased approach de-risks the entire project. We aren't just looking for gas anymore; we're building the infrastructure to sell it into a global supply vacuum. Fast, lean, and commercial—this is how you win in the current market..........

As for shorting HE1, the board has been clear that the current focus is on securing a strategic farm-out partner for the Southern Rukwa Mining Licence. Bringing in a partner is the logical next step because development and further drilling at scale will require the kind of technical expertise and capital that larger industry players bring. Until that process progresses, it makes sense that we are not seeing additional drilling activity. So if you are shorting based on no drilling going on right now with the existing kit we own or that you believe we wont find a partner to sleep with then you may do well but exercise extreme caution as I wouldn't want you to get caught with ya pants down - especially without a DOM ON.

The real near-term focus for the market isn’t another drill result — it’s progress on the farm-out discussions and securing the right partner to take the project to the next stage. That’s the step that ultimately determines how the discovery gets commercialised.

The company has already confirmed a 9.2% helium concentration at Itumbula West, which by any industry measure is a very high grade discovery. The challenge now is not proving helium exists — that has been demonstrated — but moving the project into the commercial development phase.

It’s also worth remembering that the company now holds a 480 km² Mining Licence in the Southern Rukwa Basin. That means any potential partner is looking at a permitted project with a proven helium system already identified, rather than a pure exploration licence.

A bit of perspective for anyone getting frustrated with the lack of daily updates. The bigger picture with ECR is that the company has several moving parts developing at the same time, not just the Raglan wash plant.

First, the company raised £1.5m in January from institutional investors, which suggests professional investors were comfortable with the near-term production plan and broader strategy. That funding also leaves the company with no debt, which is a strong position for a small-cap miner moving toward production.

Second, Raglan is obviously the immediate focus because it represents the potential first step into gold production and cash flow. As an AIM company, operational milestones like commissioning, production runs or gold pours generally have to come via formal RNS announcements, not social media clips, so it’s not unusual for things to appear quiet while work continues on site.

Beyond Raglan, it’s also worth remembering the wider asset base. The company still holds significant exploration ground in Victoria and continues to progress opportunities through joint ventures and partnerships, which can help move projects forward without excessive dilution. These kinds of arrangements are often how junior miners unlock value while sharing development risk.

On top of that, the company carries a large Australian tax loss position, which could become valuable to a profitable partner or acquirer in the future.

So while the market tends to focus on day-to-day noise, the actual investment case rests on three things: transition to production at Raglan, development of the wider Australian assets through partnerships, and the optionality those projects provide longer term.

For long-term holders, the key milestones to watch are confirmed production updates, any offtake or partnership news, and progress on the wider portfolio. If those pieces fall into place, the current share price will look very different in hindsight.

The debate over whether we need 'one more well' ignores the massive shift in our negotiating leverage. We aren't the same company we were a year ago. Between the 9.2% peak concentration at Rukwa and the revenue flowing from the US, we have moved from 'hoping for a deal' to 'selecting a partner...... With Qatar in force majeure and 30% of global supply offline, the industry doesn't have the luxury of waiting for a 100% 'perfect' GWR. They need secure, primary helium now. We have the proof of concept, the reservoir connectivity, and the financial shield to ensure that the next deal is a Free Carry, not a dilutive scramble. The data hasn't just driven a deal; it has secured our sovereignty....

Glad we agree—the 'work plan' and 'co-financing' are exactly what the Strategic Farm-out is designed to deliver. Whether it’s called a pilot plant or an appraisal well, the objective is the same: converting that world-class 9.2% discovery into commercial production as fast as possible. With CenerTech already familiar with the plumbing at ITW-1 and the global supply gap widening, the foundation is set for a massive re-rating. Looking forward to seeing which 'Alpha' partner steps up to the plate first.

It’s a mistake to describe Rukwa as 'on hold' when the Board explicitly launched a Strategic Farm-out on February 16 specifically to accelerate development. Galactica is a great success, but it serves as the proof-of-concept for exactly what we want to achieve at scale in Tanzania with a major partner. We aren't just 'advancing one step at a time'; we are leveraging 9.2% discovery data to secure a Tier-1 deal in the most supply-constrained helium market in history...

Bluebay, the sequence is exactly why this farm-out is so significant > a partner isn't coming in for 'proven reserves,' they are coming in for the 9.2% concentration and the massive scale we've already de-risked. In a global supply crunch, the value is in the discovery, and we have enough data right now to drive a deal that bridges the gap to production regardless of the formal paperwork. The market pays for the prize, not the certificate.